The neurotransmitter dopamine modulates vascular permeability in the endothelium

[1]  B. Yard,et al.  Hypothermia-Induced Loss of Endothelial Barrier Function Is Restored after Dopamine Pretreatment: Role of p42/p44 Activation , 2006, Transplantation.

[2]  Napoleone Ferrara,et al.  Angiogenesis as a therapeutic target , 2005, Nature.

[3]  D. Mukhopadhyay,et al.  Regulatory role of dynamin‐2 in VEGFR‐2/KDR‐mediated endothelial signaling , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  D. Cheresh,et al.  Pathophysiological consequences of VEGF-induced vascular permeability , 2005, Nature.

[5]  L. Ellis,et al.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. Cheresh,et al.  Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis , 2004, The Journal of cell biology.

[7]  S. Basu,et al.  Dopamine in vivo inhibits VEGF-induced phosphorylation of VEGFR-2, MAPK, and focal adhesion kinase in endothelial cells. , 2004, American journal of physiology. Heart and circulatory physiology.

[8]  D. Mukhopadhyay,et al.  Ablation of Peripheral Dopaminergic Nerves Stimulates Malignant Tumor Growth by Inducing Vascular Permeability Factor/Vascular Endothelial Growth Factor-Mediated Angiogenesis , 2004, Cancer Research.

[9]  S. Basu,et al.  Depleted Dopamine in Gastric Cancer Tissues , 2004, Clinical Cancer Research.

[10]  D. Antonetti,et al.  Regulation of tight junctions and loss of barrier function in pathophysiology. , 2004, The international journal of biochemistry & cell biology.

[11]  N. Himes,et al.  Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. , 2004, The Journal of clinical investigation.

[12]  H. Dvorak.  Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Napoleone Ferrara,et al.  VEGF and the quest for tumour angiogenesis factors , 2002, Nature Reviews Cancer.

[14]  Janice A. Nagy,et al.  The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor , 2001, Nature Medicine.

[15]  H. Yoshiji,et al.  The vascular endothelial growth factor receptor KDR/Flk‐1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model , 2001, Hepatology.

[16]  M. Corada,et al.  Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[17]  T. Gardner,et al.  Vascular Endothelial Growth Factor Induces Rapid Phosphorylation of Tight Junction Proteins Occludin and Zonula Occluden 1 , 1999, The Journal of Biological Chemistry.

[18]  E. Dejana,et al.  Junctional Adhesion Molecule, a Novel Member of the Immunoglobulin Superfamily That Distributes at Intercellular Junctions and Modulates Monocyte Transmigration , 1998, The Journal of cell biology.

[19]  M. Corada,et al.  Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. , 1998, Journal of cell science.

[20]  Kazushi Fujimoto,et al.  Claudin-1 and -2: Novel Integral Membrane Proteins Localizing at Tight Junctions with No Sequence Similarity to Occludin , 1998, The Journal of cell biology.

[21]  D. Mukhopadhyay,et al.  Vascular permeability factor/vascular endothelial growth factor-mediated signaling in mouse mesentery vascular endothelium. , 1998, Cancer research.

[22]  M. Lampugnani,et al.  Interendothelial junctions: structure, signalling and functional roles. , 1997, Current opinion in cell biology.

[23]  R K Jain,et al.  Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[24]  E. Dejana,et al.  Perspectives Series: Cell Adhesion in Vascular Biology Endothelial Adherens Junctions: Implications in the Control of Vascular Permeability and Angiogenesis , 1996 .

[25]  M. Lampugnani,et al.  Thrombin-induced increase in endothelial permeability is associated with changes in cell-to-cell junction organization. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[26]  B. Gumbiner,et al.  Cell Adhesion: The Molecular Basis of Tissue Architecture and Morphogenesis , 1996, Cell.

[27]  F. Breviario,et al.  Catenin-dependent and -independent Functions of Vascular Endothelial Cadherin (*) , 1995, The Journal of Biological Chemistry.

[28]  C. V. Van Itallie,et al.  Zonula occludens (ZO)-1 and ZO-2: membrane-associated guanylate kinase homologues (MAGuKs) of the tight junction. , 1995, Biochemical Society transactions.

[29]  M. Corada,et al.  Endothelial cell‐to‐cell junctions , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  M. Itoh,et al.  Direct association of occludin with ZO-1 and its possible involvement in the localization of occludin at tight junctions , 1994, The Journal of cell biology.

[31]  M. Itoh,et al.  Occludin: a novel integral membrane protein localizing at tight junctions , 1993, The Journal of cell biology.

[32]  M. Lampugnani,et al.  A novel endothelial-specific membrane protein is a marker of cell-cell contacts , 1992, The Journal of cell biology.

[33]  H. Dvorak,et al.  A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. , 1986, Cancer research.

[34]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[35]  Jeffrey W. Clark,et al.  Lessons from phase III clinical trials on anti-VEGF therapy for cancer , 2006, Nature Clinical Practice Oncology.

[36]  Y. Fujita,et al.  A novel Src kinase inhibitor, M475271, inhibits VEGF-induced human umbilical vein endothelial cell proliferation and migration. , 2005, Journal of pharmacological sciences.

[37]  R. Borchardt,et al.  VEGF increases BMEC monolayer permeability by affecting occludin expression and tight junction assembly. , 2001, American journal of physiology. Heart and circulatory physiology.

[38]  B. Katzung.  Basic and Clinical Pharmacology , 1982 .